Study of oral nizubaglustat for Niemann-Pick type C
Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests an oral medication called nizubaglustat for people with Niemann-Pick type C disease who cannot take or are not satisfied with the current treatment miglustat. It aims to see if the drug can help with symptoms like coordination and movement problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Niemann-Pick type C disease.
- You are either unable or unwilling to take miglustat, or you are unsatisfied with how well miglustat works for you.
- You are at least 4 years old.
- Your neurological symptoms (like trouble walking or coordination) started between ages 2 and 15.
- Your walking and coordination problems, measured by a doctor, are between 3 and 30 points on a scale.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medicine, nizubaglustat (AZ-3102), for children and adults (4+) with late-infantile or juvenile Niemann-Pick type C, GM1, or GM2 gangliosidosis. It aims to see if the drug is safe and helps slow disease progression.
This trial is for people with Niemann-Pick type C or GM2 gangliosidosis who are already on or have been in a related study. It tests a new drug called Nizubaglustat to see if it is safe and works better than current treatments.
This Phase 3 trial tests whether N-acetyl-leucine can improve symptoms in people with Niemann-Pick disease type C (NPC). If you qualify, you will be asked to take study medicine and complete symptom and movement tests over time.
This study measures biochemical (blood/biologic) markers and may use clinical evaluation and MRI to better understand Niemann-Pick disease type C. It could help improve how the condition is tracked and understood over time.
This trial tests an experimental drug called nizubaglustat (AZ-3102) for people with Gaucher disease type 3. It aims to see if the drug can improve symptoms like anemia, low platelets, and enlarged spleen, which are common in this condition.
This study collects health information and genetic samples from people diagnosed with Niemann-Pick disease type C. The goal is to build a large database that can help researchers better understand the condition and improve future care.
Hear when a new Niemann-Pick Type C Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.